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Abstract
Background: Huntington disease (HD) is associated with increased risk of suicide.
Objective: This study compares suicide ideation in HD to the general population, assesses 
factors associated with increased prevalence of suicidal thoughts, and compares clinician-rated to 
self-reported assessments of suicidal ideation.
Methods: We examined 496 participants with premanifest or manifest HD. Clinician-rated 
suicidal ideation was measured using the Problem Behaviors Assessment – short form. Self-
reported ideation was measured using two items from the HDQLIFE Concern with Death and 
Dying item bank. Independent sample t-tests were conducted to compare the prevalence of 
suicidal thoughts between our HD sample and the U.S. population. Logistic regression analyses 
were used to determine characteristics associated with higher odds of clinically significant suicidal 
ideation. Kappa agreement coefficients were calculated to evaluate concurrence between clinician-
rated and self-reported assessments.
Results: Our sample had a significantly higher occurrence of suicidal ideation (19.76%) and 
suicidal plans (2.1%) than the general population (p < 0.0001). Odds of clinically significant 
suicidal ideation were 6.8 times higher in females (p = 0.04) on the clinician measure, and 
Hispanic/Latinos had 10.9 times higher odds than non-Hispanics (p = 0.025) on the self-report 
measure. Clinician-rated assessment had fair agreement (k = 0.2–0.4) with self-reported 
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assessments, except in early stage HD where there was no overlap in the identification of 
participants with clinically significant suicidal ideation.
Discussion: Assessment for suicidal ideation and clinically significant suicidal thoughts in HD 
with a multimodal approach that includes clinician-rated and self-report measures is critical at all 
stages of the disease.
Keywords
Huntington disease; suicidal ideation; suicide; suicide assessment; comparing methods
INTRODUCTION
Huntington disease is an autosomal dominant, inherited, neurodegenerative disorder 
associated with an increased risk of suicidal ideation [1, 2]. This increased risk of suicide 
occurs through all stages of the disease, from the premanifest phase through onset of 
symptoms and continues as the disease progresses [3]. Opportunities to assess at-risk 
individuals for suicide and relevant risk factors occur at the time of predictive testing, during 
clinical care, and during participation in clinical research. The current study sought to 
evaluate suicide ideation in clinical research participants in the Huntington Disease Health-
Related Quality of Life (HDQLIFE) Study [4], and compare the rates of suicidal thoughts 
and clinically significant ideation to the general population, assess factors associated with an 
increased risk for suicidal ideation, and compare in-person clinician assessment of suicide 
ideation with a self-reported online assessment tool.
Huntington disease (HD) affects between 3 and 10 individuals per 100,000 worldwide [5, 6], 
and causes chorea, cognitive impairment, behavior changes, and psychiatric symptoms [2, 
7]. The pathogenic gene mutation is located at 4p16.3 and contains an expanded CAG repeat 
in exon 1 in individuals with HD [8, 9]. Average diagnosis is in the late 30 s, with the age of 
onset inversely related to the number of CAG repeats. Symptoms typically emerge gradually, 
with behavioral and cognitive symptoms commonly occurring years before motor symptoms 
[10]. Death occurs 15–20 years after symptom onset/diagnosis [2, 11, 12].
George Huntington’s original description in 1872 included a “tendency to insanity and 
suicide” as one of the peculiarities of the disease, and he comments that he was aware of 
several instances of suicide in affected and at-risk family members [13]. Reported suicide 
rates vary from 5.7% in affected persons [1] to 7.3% in affected and at-risk participants [14]. 
Farrer [1] reported that 27.6% of patients had attempted suicide at least once, which exceeds 
the general US population lifetime prevalence of 1.9–8.7% for suicide attempts [15].
Assessment of suicide risk can occur via an in-person clinical interview or completion of a 
self-report instrument. While many studies in HD utilize either the Problem Behaviors 
Assessment-short (PBA-s; 16) or the Columbia Suicide Severity Rating Scale (CSSRS; 17), 
there is no consensus for which measure should be used, nor are there standardized follow 
up procedures when someone at high risk is identified.
Wesson et al. Page 2
J Huntingtons Dis. Author manuscript; available in PMC 2019 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Additionally, clinician assessment may differ from self-reported suicide ideation. For 
example, one study found that individuals presenting for their first visit to a clinic for 
anxiety and depression were more likely to endorse current suicidal ideation on the self-
administered questionnaire than the clinician interview [18]. Similarly, a self-report 
questionnaire also was more likely to reveal increased frequency and severity of suicidal 
ideation than an in-person clinician interview in individuals with major depressive disorder 
or bipolar disorder [19]. In contrast, clinicians rated suicide ideation higher than self-report 
in patients referred from Army hospitals for depression or anxiety [20]. Furthermore, 
clinician interview assessments of suicidal ideation varied from self-reported suicidal 
thoughts by 19% in a study of patients admitted to an adult inpatient psychiatric unit that 
treated primarily mood, anxiety, eating and adjustment disorders [21]. These mixed findings 
suggest that the mode of assessment (either by self-report or through an in-person interview) 
may have an impact of how willing an individual is to report suicidal thoughts. Thus, a better 
understanding of the assessment modality in HD may help inform best practices with regard 
to suicidal ideation and suicide assessment in these individuals.
The purpose of this paper is to examine suicidal ideation, as well as the impact of 
assessment modality (in-person versus self-report survey assessment) in HD. Specifically, 
we hypothesized that the rates of suicidal ideation and clinically significant suicidal ideation 
in premanifest and manifest HD would exceed that of the general population. In addition, we 
hypothesized that individuals who are later in the disease process, as well as those with more 
clinician-rated depression, anxiety and/or anger would exhibit more severe suicidal ideation 
[22, 23]. We also hypothesized that the demographic differences in the general population 
(e.g., females have a higher prevalence of suicidal thoughts, but not suicidal plans) [24] also 
would occur in HD. Finally, we hypothesized that frequency of self-reported suicidal 
thoughts would be higher than frequency of clinician-rated suicidal ideation.
METHODS
Participants
We examined individuals with either premanifest (gene-positive for the HD CAG expansion 
and no clinical diagnosis) or manifest HD. Participants had to be at least 18 years of age, 
able to read and understand English, and have the ability to provide informed consent. 
Participants were recruited from several HD treatment centers (the University of Michigan, 
University of Iowa, University of California-Los Angeles, Indiana University, Johns Hopkins 
University, Rutgers University, Struthers Parkinson’s Center, and Washington University), as 
well as through the National Research Roster for Huntington Disease Patients and Families 
at Indiana University, existing online medical record data capture systems [25], and the 
Predict-HD study [26]. All data were collected in accordance to local Institutional Review 
Boards (IRB) and participants provided informed consent prior to study participation.
HD disease stage
The final item of the Unified Huntington Disease Rating Scale (UHDRS; 27) motor 
assessment was used to differentiate premanifest from manifest HD. This item indicates the 
“diagnostic confidence level” on a scale of 0 (no motor abnormalities) to 4 (>99% 
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confidence that motor abnormalities are unequivocal signs of HD) of the clinician’s 
impression of whether or not the participant has manifest HD. Scores lower than 4 indicate 
premanifest HD whereas a score of 4 indicates manifest HD. For manifest participants, the 
UHDRS Total Functional Capacity (TFC) was used to determine HD staging [28]. TFC is a 
clinician-rated assessment of a participant’s ability to maintain a job, manage finances 
independently, complete chores, accomplish activities of daily living [29], and live at home 
as opposed to a nursing or chronic care facility. TFC scores range from 0–13 with higher 
scores indicative of higher functioning. Stage I was defined as individuals with TFC scores 
ranging from 11–13, and Stage II was defined as individuals with TFC scores ranging from 
7–10. Stages III to V were collapsed together into one group, which was defined by a score 
of 0–6 [28].
Comparisons with the United States average
Rates of suicidal ideation and suicide planning within our sample were compared to 
published data from reports from the National Survey on Drug Use and Health from the 
Centers for Disease Control and Prevention [CDC], examining suicidal thoughts in the 
general population [24]. Respondents were asked whether they had seriously thought about 
killing themselves at any time during the past 12 months. If participants answered in the 
affirmative, they were then asked whether they had made any plans to kill themselves and 
whether they had a suicide attempt. With this information, the CDC article estimates the 
prevalence of suicidal thoughts and behaviors based on survey data from 8,360 respondents 
from 2008–2009.
Clinician-rated behaviors and suicidal ideation
Problem Behaviors Assessment – short (PBA-s; 16).—The PBA-s is a clinician-
rated measure of behavioral problems based on a semi-structured interview with patients and 
informants designed specifically for HD. Clinician raters were trained on this measure and 
required to demonstrate proficiency in its administration. It includes 11 items that examine 
different aspects of emotion and behavior including depression, suicidal ideation, anxiety, 
irritability, anger/aggression, apathy, perseverative thinking, obsessive compulsive behaviors, 
delusions, hallucinations, and disorientation. Clinicians rate each item for severity (rated on 
a scale of 0 [symptom absent] to 4 [severe] and frequency (rated on a scale of 0 [never/
almost never] to 4 [daily/almost daily for most or all of the day]). We examined frequency of 
suicidal thoughts in premanifest and manifest HD participants compared to the U.S. average, 
as well as agreement between clinician-rated and self-reported measures. Severity scores 
were utilized in our assessment of clinically significant individuals, which we defined as 
participants who had persistent suicidal ideation or have made preparations or an attempt to 
commit suicide. Participants with ratings of ≥3 for suicide severity were considered 
clinically significant, defined as severe ideation that includes a plan or prior attempt of 
suicide. For these participants, additional follow-up questions were asked to determine 
imminent risk and/or if additional referrals or treatment were warranted. Clinically 
significant suicidal ideation was coded as a dichotomous variable, either ‘Yes’ for 
participants with clinically significant suicidal ideation or ‘No’ for participants who were 
not. This variable was compared to the national U.S. estimates of individuals with a suicide 
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plan, and was also used to measure agreement between clinician-rated and self-reported 
clinically significant individuals.
Self-reported suicidal ideation
As part of a larger study, participants completed an online survey that examined their health-
related quality of life (HRQOL; details reported in 4). This study included two questions that 
assess suicidal thoughts (these items were administered as part of the HDQLIFE Concern 
with Death and Dying measure; [30]. The first question read “In the past seven days, how 
often have you thought about ending your life?” Responses were on a 5-point Likert scale 
ranging in frequency from ‘Never’ to ‘Always.’ Similar to the clinician-rated measures, self-
reported frequency of suicidal thoughts was compared to U.S. estimates. For all responses 
that were not ‘Never,’ a follow-up question was administered: “Do you intend to act on these 
thoughts in the near future?” Responses of ‘Yes’ were considered clinically significant 
(defined below). Clinically significant responses, as determined by the self-report measure, 
were compared to the U.S. estimate of the prevalence of individuals who have a suicide plan.
Clinically significant suicidal thoughts
Participants who received a severity score greater than or equal to 3 on the suicide-specific 
question on the PBAs, or who indicated ‘yes’ to the following question on HDQLIFE 
Concern with Death and Dying, “Do you intend to act on these thoughts in the near future?” 
were considered clinically significant, and required additional follow-up (as per the suicide 
assessment protocol associated with this study). The suicide protocol dictated that further 
questions to establish imminent risk were employed through direct contact (by phone or in-
person) between the study investigator or coordinator and participant. Specifically, follow-up 
questions with regard to suicidal thoughts (including frequency and persistence of these 
thoughts), details with regard to a plan, identification of future reasons to live, as well as 
previous history of attempts were queried to determine if there was imminent risk. In all 
cases of endorsement, the study site investigator was notified, consulted, and follow-up 
actions documented. In cases where imminent risk was identified the study site investigator 
made the appropriate referrals following professional standards of conduct, including 
contacting emergency services if needed.
Analysis plan
Frequency counts for endorsement of the suicide assessment items on the PBA-S and the 
two self-report suicidal ideation questions from the Concern with Death and Dying measure 
were calculated using SAS 9.4.
Suicidal ideation prevalence in HD relative to the U.S general population
Four separate independent sample t-tests were conducted to compare the prevalence of 
suicidal thoughts between the CDC’s U.S. average and our sample. The first two t-tests 
compared the proportion of individuals with suicidal ideation between the U.S. population 
and our measures (i.e., the PBA-s and HDQLIFE survey) of suicide frequency in HD. For 
these tests, our frequency measures were dichotomized into “no suicide ideation” or “suicide 
ideation present.” Another t-test compared rates of individuals in our cohort with persistent 
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suicidal ideation and/or plans to act on these thoughts in the future, with rates of individuals 
within the U.S. population with suicidal thoughts. A final t-test compared the proportion of 
HD participants who were clinically significant based on our measures of suicidal ideation 
(i.e., PBA-s and HDQLIFE survey) to the proportion of individuals within the U.S. 
population with a suicide plan.
Demographic risk factors for suicidal ideation in HD
In addition, crude and adjusted logistic regression analyses were used to determine which 
characteristics relate to higher odds of an individual having clinically significant suicidal 
ideation. First, we wanted to determine if the demographic factors (i.e., gender, age, race, 
and ethnicity) related to increased odds of having a suicide plan (CDC Morbidity and 
Mortality Weekly Report; MMWR) [24] were present in our HD sample. Each of these 
demographic variables were entered individually into a logistic model with the outcome of 
clinically significant suicidal ideation. Next, logistic regression models determined if staging 
and PBA-s total scores of depression, anxiety, and anger/aggression relate to higher odds of 
clinically significant suicidal ideation. These variables were selected based upon the 
established relationship between emotional distress and suicidal ideation [22, 23].
Concordance between self-reported and clinician-rated suicidal ideation
Next, a Kappa agreement coefficient [31] was used to evaluate agreement between the 
frequency of the clinician-rated suicide assessment (i.e., PBA-s), and self-report questions. 
In addition, Kappa coefficients were used to examine agreement between suicide protocol 
activation based on the clinician-rated questions, compared to suicide protocol activation 
based on the self-report questions. A kappa score between 0.81 and 1.00 was considered 
almost perfect agreement, 0.61–0.80 was considered substantial agreement, 0.41–0.60 was 
moderate agreement, 0.21–0.40 was deemed fair agreement, and lower than 0.20 indicated 
no agreement [31, 32]. Paired t-tests comparing frequency scores for self-report and 
clinician rated measures were used to determine whether one measure had a higher average 
score than the other.
RESULTS
Participants
We examined 496 individuals with either premanifest (n = 194) or manifest HD (Stage I n = 
79; Stage II n = 113; and Stage III-V n = 110; Table 1). Groups did not differ on gender (χ23 
= 5.02, p = 0.1705), but, as expected, age differed (F[3, 492] = 29.31, p < 0.0001). The 
average age of the premanifest group x = 42.7  was nine years younger than the Stage I 
group x = 51.1 , 10 years younger than the Stage II group x = 52.4 , and 13 years younger 
than the Stage III-V group x = 54.7 . This finding is expected, as symptoms of HD progress 
over time [2]. The Stage III-V group included a greater proportion of African Americans 
than the premanifest and Stage I and Stage II groups (Fisher’s Exact = 0.0013), whereas 
ethnicity did not differ across groups (χ26 = 11.10, p = 0.09). Education differed between 
the four HD groups (F[3, 490] = 12.21, p < 0.0001), as the pre-manifest group had more 
years of education than the Stage II and Stage III-V groups. Additionally, the Stage III-V 
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group had a higher number of CAG repeat lengths than the premanifest group (F[3,381] = 
4.93; p = 0.0023).
Suicidal ideation prevalence in HD relative to the U.S general population
Published rates of suicidal thoughts in individuals over the age of 18 in the US indicate that 
approximately 3.7% (95% CI: 3.5, 3.9) of individuals endorse suicidal thoughts and 1% 
(95%CI: 0.9, 1.1) have a suicide plan [24]. Our self-report measure revealed that 19.76% 
(95%CI: 16.3, 23.2) of participants endorsed some degree of suicidal thoughts, which 
exceeded the US average [t(8853) = 35.0186; p < 0.0001]. Similarly, our survey indicated 
that 2.01% (95% CI: 0.8, 3.2) of our sample planned to act on these thoughts in the near 
future, which is significantly higher than the US average (t[2757] = 427.04; p < 0.0001). The 
clinician rated measure showed a 11.10% (t[8853] = 35.02; p < 0.0001) prevalence of 
suicidal ideation with approximately 2.42% (t[2757] = 425.02; p < 0.0001) of participants 
endorsing intention to act on these thoughts in the near future.
Demographic risk factors for suicidal ideation in HD
For clinician-rated suicidal ideation, females had a 6.8 times (OR = 7.88, 95% CI: 1.01, 
61.554; p = 0.04; Table 2) greater risk of clinically significant suicidal ideation than males, 
similar to the U.S. population. However, this finding did not remain significant when 
controlled for depression, anger and anxiety. None of the other demographic variables (i.e., 
race, ethnicity, age, or education) significantly related to clinically significant suicidal 
ideation. Late-stage participants did not have greater risk of clinically significant ideation 
than either early-stage or premanifest participants. Higher levels of clinician rated 
depression (OR = 1.47, 95% CI:1.28, 1.70; p < 0.0001), anger (OR = 1.30, 95% CI: 1.14, 
1.49; p < 0.0001), and anxiety (OR = 1.28, 95% CI: 1.13,1.44; p < 0.0001) indicated greater 
risk of clinically significant suicidal ideation. In the adjusted model, clinician-rated 
depression (OR = 1.44, 95% CI: 1.21,1.71; p < 0.0001) was associated with clinically 
significant suicidal ideation. However, anger/aggression (OR = 1.21, 95% CI: 1.00, 1.46; p = 
0.05), anxiety (OR = 1.01, 95% CI: 0.87, 1.18; p = 0.85) and female gender (OR = 8.21, 
95% CI: 0.88, 76.53; p = 0.06) did not.
Based upon self-reported suicidal thoughts, ethnicity was the only demographic variable to 
have an association with clinically significant suicide ideation in our HD group which differs 
from demographic differences in suicidal ideation in the US population. Participants who 
identified as Hispanic or Latino had a 10.9 (OR = 10.9, 95% CI: 1.33, 86.88; p = 0.03) times 
higher risk of clinically significant suicidal ideation than non-Hispanics or Latinos. 
Depression was a significant risk factor of suicidal ideation as well (OR = 1.19, 95% CI: 
1.02, 1.38; p < 0.0001), but neither anxiety nor anger/aggression were associated with 
clinical significance. In an adjusted model, both depression (OR = 1.18, 95% CI: 1.01, 1.38; 
p = 0.04) and ethnicity (OR = 9.23, 95% CI: 1.08, 78.53; p = 0.04) remained significant.
Concordance between self-reported and clinician-rated suicidal ideation
Clinician-rated suicidal ideation—Overall, 11.10% of all participants had a score 
higher than 0 (Never) on the suicidal thoughts question of the PBA-s (Table 3). The 
frequency of suicidal ideation did not differ among the four HD groups (Fisher’s Exact p = 
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0.61 Table 3). Overall, we enacted our suicide protocol for 2.27% of the sample based upon 
the clinician-rated measure(s). Suicide protocol activation also did not differ among the four 
HD groups (Fisher’s Exact p = 0.66; Table 3).
Self-reported suicidal ideation—Overall, 19.76% of participants endorsed suicide 
ideation on the self-report assessments (Table 3). Suicide endorsement did not differ among 
the four HD groups (Fisher’s Exact p = 0.28; Table 3). Overall, we enacted our suicide 
protocol for 1.99% of our study participants based upon the self-report measure(s). The 
suicide protocol activation did not differ among the four HD groups (Fisher’s Exact p = 
0.57; Table 3).
Comparisons between clinician-rated and self-report measures—Of the five 
Stage I and three Stage II participants who were clinically significant, four were indicated 
solely by the clinician measure and four were indicated solely by the self-report measure, 
with no overlap. This indicates that for Stage I and Stage II individuals, the two measures of 
clinically significant suicide ideation did not agree (κ = -0.1538 and -0.0541, respectively; 
Table 4). The remaining Kappa coefficients indicated that the clinician measure of suicidal 
ideation and the self-report measure had fair agreement (κ = 0.2–0.4) for suicide frequency 
and clinically significant risk. The exception to this was in the premanifest participants, in 
which there was substantial agreement between the two measures of clinically significant 
suicidal ideation (κ = 0.6296; Table 4). Participants typically reported greater frequency of 
suicidal ideation during the survey than on the clinician measure (t[495] = -5.02; p < 
0.0001).
DISCUSSION
This study confirms that individuals with premanifest and manifest HD have rates of suicidal 
ideation and having a suicide plan higher than the general population [24]. In fact, rates for 
self-reported suicidal ideation were more than five times greater than rates in the general 
population (19.76% in HD relative to 3.7% in the general population). Furthermore, the rate 
of individuals with HD that had a plan for suicide was two times that of the general 
population (2.01% in HD relative to 1% in the general population). Findings were similar, 
although less robust, for clinician-rated suicidal ideation. In this case, clinicians indicated a 
prevalence rate of 11.10% for suicidal ideation for these same individuals (relative to the 
19.76% based on self-report data). These findings are consistent with previous findings of 
suicidal ideation estimates in this population [33–35]. Clinician-rated measures of suicide 
plans were comparable to the self-report measures (2.42% for clinician-rated versus 2.01% 
for self-reported rates), however, for participants in Stage I and Stage II the two measures 
did not overlap. One explanation could be that the self-reported measure asks about suicide 
ideation in the past seven days, whereas the clinician-rated measure asks participants about 
their situation within the past month, which increases the risk for recall bias. The receipt of a 
clinical diagnosis is an emotionally tumultuous time that may enhance variability of 
reporting suicidal ideation.
In addition to the general rates for suicidal ideation and suicide plans, we examined different 
risk factors for clinically significant suicidal ideation. First, findings suggested that females 
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were more likely than males (6.8% more likely) to report clinician-rated, but not self-
reported, clinically significant suicidal ideation. While the finding for clinician-rated risk is 
consistent with findings in the general population (which also suggest that females have a 
higher prevalence than males in regards to suicidal thoughts; 24), the absence of this finding 
for self-reported risk was more surprising.
Second, none of the other demographic factors that relate to risk in the general population 
were found with clinician-rated risk (i.e., that suicidal thoughts and plans are more prevalent 
in individuals aged 18–29 [than older participants], in non-Hispanic whites [relative to other 
races/ethnicities], and in those with a high school education [relative to those with more 
education. Being Hispanic or Latino related to increased risk with the self-report measure, in 
contrast to the general population [24]. This unexpected finding seems to contrast with 
studies that reported lower suicide rates in Hispanics relative national (US) rates for 
Hispanics, [36] as well as similar rates of lifetime suicide attempt among whites, blacks and 
Hispanics [37]. To the best of our knowledge, there have been no studies that examined 
suicidal ideation in Hispanics living with chronic conditions, which may provide a potential 
explanation for this finding. Given the small number of Hispanic or Latino participants in 
our study (n = 12), further investigation is warranted.
Third, contrary to our hypotheses, disease stage (premanifest, early- or late-HD) did not 
relate to increased risk of either clinician-rated or self-reported clinically significant suicide 
ideation. This finding agrees with another study in HD that did not find a relationship 
between TFC and suicidality [35], but appears inconsistent with other HD literature. Disease 
stage may not relate to suicidal ideation in HD, however methodological differences 
between this sample and other studies may explain this discrepancy. First, this study used 
different measures to assess suicidal ideation. This study employed the PBA-s (a clinician-
rated instrument that measures behavior over the last four weeks) and a single self-report 
item about suicidal thoughts (within the past week), whereas other studies used the BDI-II to 
assess suicidal thoughts (within the past 2 weeks), the UHDRS assessment of suicidal 
thoughts and attempts over the past six months, and the C-SSRS which assesses lifetime 
suicidal thoughts and attempts.
Our findings suggest that other than gender, demographic factors may not play a major role 
in suicidal ideation in this population. Findings from the National Comorbidity Survey 
suggest that simply having a chronic illness increases one’s risk of suicidal ideation [38]. In 
addition, a study conducted within the Mental Health Research Network found that 17 of 19 
physical health conditions were associated with an increased risk of suicide and having 
multiple physical health conditions significantly increased suicide risk [39]. Thus our sample 
may have been more affected by just having a chronic disease, rather than the severity of 
their HD (i.e., disease stage). The high risk of suicide in individuals with HD likely reflects 
the lack of an available cure to this relentlessly progressive condition [1, 2]. Alternatively, 
individuals with clinically significant suicide ideation may not share their distress either in 
person or via self-report survey, because they do not want help [40, 41] or to avoid 
involuntary hospitalization [42, 43]. In addition, clinician-rated risk and self-reported risk 
yield similar, but not identical, findings; thus further examination of demographic factors 
such as gender and Hispanic ethnicity warrant further exploration in HD.
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As expected clinician-rated depression and anger related to greater risk for clinically 
significant suicide ideation. Only depression remained a significant risk factor for clinically 
significant suicidal thoughts whereas other self-reported symptoms did not. The relationship 
between depression and suicidal ideation in HD resembles the strong relationship found in 
both the HD population [34, 44] as well as other populations [22, 23, 45]. Also not 
surprisingly, anger related to suicide risk in HD, as it does in other groups [23, 46]. 
Interestingly, self-reported risk did not reveal this relationship, perhaps suggesting that those 
with HD are less apt to share or have less awareness of their own anger.
In general, individuals with HD were more likely to endorse suicidal ideation via self-report 
than via in-person interview similar to other groups [18, 19]. Finally, although clinician-
rated measures reasonably agreed with self-reported suicidal ideation (with substantial 
agreement for premanifest participants), clinician-rated suicide significance did not agree 
with self-reported suicide actionable risk. This suggests that these assessment modalities 
identify different individuals that need intervention. Thus both assessment modalities should 
be considered to maximize identification of those most likely to engage in a suicide plan.
The current study found that female gender and Hispanic/Latino ethnicity related to an 
increased occurrence of suicidal ideation in premanifest and manifest HD. Additional factors 
to consider in evaluating suicide risk in HD (which were not assessed in the current study) 
include substance dependence, psychiatric history, hopelessness, irritability, emotional 
distress, sleep disturbance, ego strength, suicidal ideation, history of suicide attempts, 
unemployment, motor status, and social dysfunction [23, 39, 45, 47–50]. All should be 
considered when determining best practices for evaluation of suicidal ideation in this 
population.
Future research should focus on the identification of existing HD suicide risk assessment 
practices within clinical and research settings. A goal of this research should be to develop 
formal guidelines for best practices and a standardized assessment for suicide risk in those 
individuals that are at risk for or have premanifest or manifest HD. The findings from this 
study would suggest that best practices for assessment of risk should include multiple 
assessment modalities to ensure that those individuals that are experiencing these thoughts 
and feelings are identified and provided with appropriate interventions. The goal should be 
to maximize the identification of those at-risk and thus ensure that all individuals with 
suicidal ideation are identified, as the potential consequence of not identifying someone is 
death.
While these findings have important implications for assessing suicidal ideation and 
clinically significant suicide in HD, we recognize several study limitations. First, we 
examined thoughts of suicide and suicide plans but did not have consistent data about past 
history of suicide attempts. A past history of suicide attempt confers a significant risk factor 
for future attempts in the general population [51], and future work could determine if this 
holds for HD. In addition, the online and clinician-rated assessments were not identical. The 
clinician measure provided numerical descriptions for frequency (e.g., once per week, every 
day) while the online assessment had qualitative options (e.g., rarely, or sometimes). 
Therefore, participants may have interpreted the online assessment differently from other 
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participants or the clinician measure. In addition, the demographics of our sample may limit 
the generalizability of our findings. Our sample was highly educated in comparison to the 
general population, and was primarily white as evident by the small proportion of African 
American (1.8%) and Hispanic/Latino (2.4%) participants. While the CDC estimates for 
suicidal ideation for White, non-Hispanic participants was only slightly above the overall 
estimate (3.9% compared to 3.7%), the homogenous makeup of our sample must be 
considered when interpreting our comparisons to the general population. Furthermore, the 
small proportion of Hispanic participants in our study, as well as the small number of 
participants who endorsed clinically significant suicide ideation on the survey (N = 10) may 
have altered the results of the logistic regression model. On the survey, 2 Hispanic 
participants (17%) had clinically significant suicidal ideation compared to 8 non-Hispanic 
participants (1.7%), thus a single Hispanic participant who endorses suicidal plans held 
more weight than a single non-Hispanic participant.
As expected, rates of suicide in HD significantly exceed that in the general population. 
Furthermore, the typical demographic risk factors for suicidal ideation in the general 
population were not apparent in this HD sample. Thus, having premanifest or manifest HD 
warrants increased attention to suicide risk; therefore, clinicians should feel comfortable 
raising concerns about suicide with their patients to provide or refer to appropriate clinical 
services. Furthermore, symptoms of depression and anger also should alarm clinicians to 
further investigate feelings of suicide with their patients. Finally, clinicians should use 
multiple modes of assessment for suicidal ideation since self-report surveys and in-person 
interviews identified different individuals with clinically significant suicidal ideation. The 
threshold for concern should be low to maximize identification of those with suicidal 
ideation. This extra effort to identify those extremely distressed individuals with greater risk 
for suicide may save lives.
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ADL Activities of Daily Living
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HD Huntington disease
HDQLIFE Huntington Disease Health-Related Quality of Life
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MMWR Morbidity and Mortality Weekly Report (published by Centers for Disease 
Control)
PBA-s Problem Behaviors Assessment-short
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Table 1
Demographic Characteristics of Individuals with HD, stratified by disease stage
Variable Premanifest (N = 194) Stage I (N = 79) Stage II (N = 113) Stage III-V (N = 110) All (N = 496)
Age (years)
 M(SD) 42.7 (12.1) 51.1 (13.5) 52.4(11.7) 54.7(11.9) 48.9 (13.2)
Gender (%)
 Female 63.9 49.4 58.4 58.2 59.1
 Male 36.1 50.6 41.6 41.8 40.9
Race (%)
 White 97.4 96.2 98.2 93.6 96.6
 African American 0.0 0.0 0.0 6.4 1.8
 Other 2.1 3.8 1.8 0.0 1.4
 Not Provided 0.5 0.0 0.0 0.0 0.2
Ethnicity (%)
 Not Hispanic or Latino 92.7 89.9 94.7 96.8 93.6
 Hispanic or Latino 1,5 6.3 2.7 0.8 2.4
 Not Provided 5.9 3.8 2.7 2.4 4
Education (# of years)
 M(SD) 15.9 (2.9) 15.4(3.1) 14.3 (2.5) 14.2 (2.6) 15.1 (2.9)
Marital Status (%)
 Single, Never Married 16.5 16.5 14.3 10.9 14.8
 Married 67.0 51.9 54.5 62.7 60.8
 Separated/Divorced 13.9 21.5 25.9 22.7 19.8
 Widowed 0.0 2.5 3.6 3.7 2.0
 Living with Partner 2.6 7.6 1.8 0.0 2.6
CAG Repeats
 M (SD) 42.1 (2.9) 43.4 (4.5) 42.8 (3.3) 44.4 (6.9) 42.8 (4.1)
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Table 2
Odds Ratios for Individuals with Clinically Significant Suicidal Ideation
OR 95% CL P
Clinician-Rated Measure
 Depression 1.44 (1.21, 1.71) <0.0001
 Anger/Aggression 1.21 (1.00, 1.46) 0.05
 Anxiety 1.01 (0.87, 1.18) 0.85
 Gender 8.21 (0.88,76.53) 0.06
Self-Report Measure
 Depression 1.19 (1.02, 1.38) 0.04
 Hispanic or Latino 9.23 (1.08,78.53) 0.04
 Ethnicity not Provided <0.001 (<0.001, >999.99) 0.98
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Table 4
Kappa (k) coefficients comparing agreement between the clinician rated measure and self-report measure
Frequency Clinically Significant Suicidal Ideation
Premanifest 0.3214 0.6296
Stage I 0.3850 -0.1538
Stage II 0.1750 -0.0541
Stage III-V 0.3140 0.1818
All 0.2678 0.2031
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